Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lundbeck

- PMLiVE

Schultz takes Lundbeck helm after leaving Novo Nordisk

Former executive left Danish firm just days ago

- PMLiVE

Brintellix first antidepressant with cognition claim in Europe

Trial found it performed better than Lilly’s rival Cymbalta

- PMLiVE

ViiV maintains top spot in reputation survey

But former top-ranked Gilead slides down in PatientView poll of patient groups

- PMLiVE

FDA approves AbbVie’s Duopa in advanced Parkinson’s

Drug is administered into the stomach via a tube

- PMLiVE

NICE backs drug to cut alcohol consumption

Final guidance for Lundbeck’s Selincro for use on NHS in England

- PMLiVE

MRC Technology and Yabao form Parkinson’s partnership in China

Companies will target specific kinase involved in neurodegeneration

- PMLiVE

Lundbeck CEO resigns after rule breach

Ulf Wiinberg accepted gift of shares in Stratified Medical

- PMLiVE

Charity coalition pledges millions for brain disease research

Will invest £30m developing candidates for neurodegenerative conditions

- PMLiVE

Lundbeck still feeling effects from Cipralex patent loss

The antidepressant sales dropped another 33% in the third quarter

- PMLiVE

NICE recommends Lundbeck’s alcohol dependency drug

NHS patients to have access to Selincro to help control drinking

- PMLiVE

Lundbeck launches Brintellix in first EU market

The antidepressant set to sell worldwide

- PMLiVE

Otsuka and Lundbeck file Abilify follow-up in the US

Brexpiprazole to be reviewed for use in schizophrenia and major depressive disorder

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links